Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)|Stage IIb Breast Cancer (T3N0)
Interventions: OTHER: Whole-body FDG PET-CT alone
Sponsor: Ontario Clinical Oncology Group (OCOG)
Collaborators: Cancer Care Ontario